Although ADPN has potential to be developed as a biopharmaceutical for various metabolic diseases, its relatively high serum concentration, and complex multimeric structure have been major bottlenecks hampering its development as a cost-effective therapeutic agent. Here, ADIPOQ is linked to metabolic disease.